background: one million people are diagnosed with gastric cancer (gc) annually and the prognosis for patients with advanced gc or gastroesophageal junction (gej) cancer is usually poor with a median survival time of 8 to 10 months. recent reports have identified that anti her2 target therapy improved the median survival rate in patients with her2 positive gc; but a wide range of her2 overexpres...

BACKGROUND AND AIM The familial aggregation of Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction, jointly termed familial Barrett's esophagus, may represent a complex genetic trait. The aim of this study was to determine the proportion of patients with these diseases who have familial Barrett's esophagus. METHODS Information on gastroeso...

OBJECTIVE This study was conducted to investigate the efficacy and safety of using a concurrent neoadjuvant chemoradiotherapy (a XELOX regimen) to treat adenocarcinoma of the gastroesophageal junction. METHODS Seventy-six patients having resectable adenocarcinoma at the gastroesophageal junction (T3/4, N+, M0) were recruited to participate and randomly assigned to either a chemoradiotherapy g...

AIM To investigate the incidence and risk factors of microscopically positive proximal margins in Chinese patients with adenocarcinoma of the gastroesophageal junction. METHODS The medical records of 483 patients, who underwent surgical treatment with curative intent for adenocarcinoma of the gastroesophageal junction in a single high-volume tertiary medical center, were reviewed. Demographic...

Barrett esophagus was found in seven members of a single family. Two of these patients also had adenocarcinoma of the gastroesophageal junction. Among family members who did not have Barrett epithelium, one had esophageal ulcerations with dysplasia in squamous epithelium and another had an esophageal stricture. The pattern of involvement suggests autosomal dominant inheritance of Barrett esopha...

A 52 year old female presented with a Siewert's type III gastroesophageal junction (GEJ) adenocarcinoma treated with neoadjuvant chemotherapy, laparoscopic-robotic total gastrectomy, and adjuvant chemoradiation.

background: recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. however, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less investigated. the present study evaluated the outcome and mid-term survival of patients with gastric ...